Peter Lebowitz, CEO of Third Arc Bio, shared a post on LinkedIn by Third Arc Bio, adding:
“Proud to share news of a strategic collaboration between Third Arc Bio and Adagene that brings together two powerful technologies to address one of the biggest challenges in solid tumor immunotherapy: precision.
This partnership underscores our pursuit of a novel approach and commitment to reshaping how hard-to-treat cancers are addressed.”
Quoting Third Arc Bio’s post:
“Today, we are excited to announce a strategic licensing agreement with Adagene – a partnership that combines the power of Third Arc Bio’s ARCStim Platform with the proven, tumor-specific activation capabilities of Adagene’s masking technology. This collaboration allows us to address a larger array of solid tumor targets with our ARCStim Platform.
More posts featuring Peter Lebowitz.